Clinical Trials / Research Studies
Medulloblastoma Relapse / Refractory

Medulloblastoma Relapse / Refractory

Showing 11 - 15 of 15 records.

PBTC-060: A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

  • Ages: 1 Year to 21 Years

This is a multicenter pilot study of SurVaxM (SVN53-67/M57-KLH) for children and young adults with progressive or relapsed medulloblastoma, high grade glioma, ependymoma and newly diagnosed diffuse intrinsic pontine glioma. Survivin (BIRC5) is an inhibitor of apoptosis (IAP) protein that is highly e ...More

PEPN2111: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Ages: 1 Month to 30 Years

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block sig ...More

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  • Ages: 2 Years to 20 Years

This study will evaluate palbociclib in combination with chemotherapy (temozolomide and irinotecan) in children, adolescents and young adults with recurrent or refractory solid tumors. The main purpose of this study is to evaluate the safety of palbociclib in combination with chemotherapy in order t ...More

Testing the Safety and Tolerability of CX-4945 in Patients with Recurrent Medulloblastoma Who May or May Not Have Surgery

  • Ages: 3 years or older

Phase I component is a dose-escalation study. The Phase II component is to establish the safety of 1000mg BID given continuously. The study will open with a safety cohort of 3 subjects who are considered skeletally-mature. The initial 3 subjects will be administered CX-4945 twice a day at the adult ...More

Volitinib in Treating Participants with Recurrent or Refractory Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma

  • Ages: 6 Years to 21 Year

This phase I trial studies the best dose and side effect of volitinib in treating participants with Medulloblastoma, High-Grade Glioma or Diffuse Intrinsic Pontine Glioma that have come or does not respond to treatment. Volitinib may stop the growth of tumor cells by blocking some of the enzymes nee ...More

Previous Page12Next Page

Contact Us

Contact us.

To learn more about available clinical trials related to brain and spinal tumors, contact us at cancer@cchmc.org or 513-636-2799.

Related Studies

Give Today

3333 Burnet Avenue, Cincinnati, Ohio 45229-3026

© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.

U.S. News & World Report Honor Roll Badge for Top Children's Hospital.Best Places to Work.America's Best Large Employers